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Introduction
Nasopharyngeal carcinoma (NPC) is a rare tumor in the
United States and Western Europe, with an incidence
of 0.5 to 2 per 100,000 [1]. In contrast, NPC is far
more common in southern China where incidence rates
as high as 25 to 50/100,000 per year have been reported
[2]. NPC has a bimodal age distribution. A small peak
is observed in late childhood, and a second peak occurs
in people aged 50–60 years, and male to female ratio
ranges from approximately 2:1 to 3.5:1 [1]. The scarcity
and deep-seated location of NPC often delays diag-
nosis and presents with an advanced-stage tumor at
diagnosis. The etiology of NPC suggests at least three
major factors: environmental factors [3], viral infection
(EB virus), [4] and genetic factor (deletion of 3p and
16q, heredity, molecular pathogenesis) [5].
Cancer complication is approximately 1 per 1,000
pregnancies [6] and is rarely found as nasopharyngeal
cancer [7–9]. The evaluation and treatment of preg-
nant women with cancer are generally similar to those
of nonpregnant women with a few exceptions. The
risks associated with chemotherapy or radiation ther-
apy depend on the gestational age and the dosage of
antineoplastic agents and radiation dose. This report
describes a pregnant woman in which advanced-stage
NPC was diagnosed, and two successful pregnancy out-
comes were achieved after tailored use of a combination
of chemotherapy and radiotherapy.
Case Report
A 26-year-old Taiwanese primigravida received regular
antenatal care at a local hospital. Unfortunately, she
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SUMMARY
Objective: Nasopharyngeal carcinoma, particularly during pregnancy, rarely comes to medical attention before
it spreads to the regional lymph nodes.
Case Report: We report a 26-year-old Taiwanese woman who suffered from persistent headache and purulent
nasal discharge during mid-pregnancy. Magnetic resonance imaging examination showed a large soft tissue
mass measuring 3×2×2 cm in the left nasopharynx at 31 weeks of gestation. Punch biopsy of the tumor was
done, and the histopathologic report revealed poorly differentiated, non-keratinizing type of squamous cell 
carcinoma (T4N2M0). A female infant weighing 1,790 g was delivered by cesarean section at 33 weeks of gesta-
tion with Apgar scores of 5 and 8 at 1 and 5 minutes, respectively. The patient received chemotherapy and radi-
ation therapy after delivery. She was disease-free for 3 years. Subsequently, the patient delivered a second healthy
infant weighing 3,084 g in a consecutive pregnancy, with a 3-year birth interval. Her first and second child
showed normal psychomotor development at 3 years and 6 months of age, respectively.
Conclusion: The possibility of rare nasopharyngeal carcinoma should be considered in any pregnant woman
with presenting symptoms of persistent headache and abnormal nasal discharge, and a detailed thorough
investigation is indicated. Successful pregnancy outcome can be achieved after tailored use of a combination of
chemotherapy and radiotherapy. [Taiwan J Obstet Gynecol 2007;46(4):423–426]
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■ CASE REPORT ■
suffered from nasal discharge and headache, especially
in the left parietal area 3 months prior to admission.
Initially, she visited a neurologist at a tertiary care hos-
pital for further evaluation. Brain computed tomogra-
phy was performed, revealing a negative finding. The
impression was that of common cold with rhinitis, 
and she received medication at that time. She was re-
ferred to our emergency department because of per-
sistent headache, and paranasal sinusitis was suspected
owing to purulent nasal discharge. However, a large
nasopharyngeal mass was noted after nasopharyngo-
scopic examination. Punch biopsy of the tumor was
done, and the pathologic report revealed squamous
cell carcinoma that was poorly differentiated and of
the non-keratinizing type. Because of the intractable
headache and pregnant state, she was admitted for
tumor survey. Magnetic resonance imaging (Figures 1
and 2) revealed a large mass 3×2×2 cm in the left
nasopharynx, loss of fat signal intensity over the petrosal
apex of the left temporal bone and left-side pterygoid
process of the sphenoid bone, bone destruction of the
skull base by the tumor, and minimal soft tissue over
the left parasellar region; and intracranial invasion
was considered to be present. Under the impression of
advanced-stage NPC (T4N2M0), a radiation oncology
doctor was consulted and combined chemoradiother-
apy was suggested. She underwent elective cesarean
section at 33 weeks’ gestation, and a female infant
weighing 1,790 g was delivered with Apgar scores of 
5 and 8 at 1 and 5 minutes, respectively. Six days after
delivery, chemotherapy with cisplatin 60 mg/m2 at
day 1 and 5-fluorouracil 2,500 mg/m2 plus leukovorin
250 mg/m2 at day 8 repeated every two weeks was
given for five courses smoothly. Radiation therapy was
performed by intensity-modulated radiation therapy
with dose 7,000 cGy divided into 35 fractions deliv-
ered in 7 weeks by 6 MV photon beam from a linear
accelerator. Complete regression of the tumor was ob-
served by nasopharyngoscopy and computed tomog-
raphy scan 3 months after radiotherapy. She received
regular follow-up and tumor survey during the next 
3 years, with no evidence of tumor recurrence. Sub-
sequently she conceived again and received antenatal
care at our institution. She underwent repeat cesarean
section, and a healthy male infant weighing 3,084 g was
delivered with Apgar scores of 8 and 9 at 1 and 5 min-
utes, respectively, with a 3-year birth interval. She was
discharged in stable condition. Furthermore, she received
restaging work-up in September 2006, and all surveys,
including tomography of nasopharynx, whole body bone
scan, abdominal sonography and chest X-ray, showed no
evidence of tumor recurrence. Her first and second child
showed normal psychomotor development at 3 years
of age and 6 months of age, respectively.
Discussion
The incidence of malignancies during pregnancy has
increased in recent decades. The most common malig-
nancies associated with pregnancy are cervical, breast,
melanoma, ovarian and hematologic cancers (leukemia
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Figure 1. Axial T1-weighted image demonstrates a large iso-
intense signal intensity tumor (arrow) measuring 3×2×2 cm
in the left nasopharynx.
Figure 2. Coronal T2-weighted image depicts skull base
tumoral invasion, which is of moderately low signal intensity
(arrow).
and lymphoma) [6], but NPC is rarely found during
pregnancy. NPC occurs with a high frequency in Chinese
people, especially in those from the southern provinces
of China and Taiwan [10]. The incidence of NPC in
Taiwan is 8.3/100,000 in the male and 3.5/100,000 
in the female population [11]. It has been the sixth
leading malignant tumor for women in Taiwan since
1983. The histopathologic type of more than 90% of
patients is undifferentiated or non-keratinizing squa-
mous carcinoma and is diagnosed at a mean age of
around 45 years.
NPC originates in the fossa of Rosenmuller. This is
an occult site, and patients often remain asymptom-
atic for a prolonged period. The most common pre-
senting nasal symptoms include bleeding, obstruction
and discharge (77.5%), ear symptoms including deaf-
ness and tinnitus (73%), headache (61%), and neck
swelling (60%). The clinical triad of a neck mass, nasal
obstruction with epistaxis, and serous otitis media
occurs infrequently. Bone erosion into the skull base
with or without cranial nerve impairment is common
at diagnosis. In a study, skull base invasion was seen in
63% of the 150 patients at presentation [12]. Cranial
nerves III to VI are most commonly affected. In con-
trast to other epidermoid cancers of the head and
neck, NPC has a greater tendency for early metastatic
spread [1].
Adverse prognostic features include cranial nerve
palsies, involvement of the paranasopharyngeal space,
advanced age, male sex, and involvement of the lymph
nodes. The prognosis is worse with distal lymph node
involvement proceeding from the upper cervical chain
to the middle and lower cervical chain.
Yan et al [7] reported 27 cases of NPC in which 
the patients were found either to be pregnant during
treatment or to have given birth to children after radio-
therapy. Nine patients were discovered to be pregnant
during treatment (the concurrent group), and 18 pa-
tients became pregnant during their follow-up period
after radiotherapy (the subsequent group). In the con-
current group, only one patient survived for more than
five years without any evidence of tumor recurrence.
All the other patients died within one and a half years
after radiation. In the subsequent group, 83% (15/18)
of patients were living and disease-free for 5 years or
more after therapy. Wong et al [8] reported a case in
which NPC was diagnosed at 21 weeks’ gestation, and
the patient received irradiation treatment with the use
of 6 million electron volts photon beam from the lin-
ear accelerator. The total dose to the nasopharynx was
6,250 cGy in 29 fractions over 6.5 weeks and to the
neck in 3,920 cGy in seven fractions over 6 weeks. Fetal
growth was assessed biweekly by ultrasound. Normal
fetal growth was observed throughout the pregnancy,
and the baby weighing 3,700 g was delivered at 38
weeks’ gestational age by cesarean section.
Lin et al [13,14] reported that concurrent chemora-
diotherapy is superior to radiotherapy alone for low-risk
patients. Adding neoadjuvant and/or adjuvant chemo-
therapy would be a reasonable approach for high-risk
patients. However, chemotherapy or radiation therapy
during pregnancy is a challenge to the obstetrician. For
NPC, major regimens of chemotherapy are cisplatin
and 5-fluorouracil. Cisplatin (risk factor DM) is an anti-
neoplastic used in the treatment of various cancers.
This agent produces a chromosomal aberration in nor-
mal cell in the tissue culture and is teratogenic and
embryotoxic in mice. It is also a transplacental carcino-
gen in rats, producing tumors in the liver, lung, nervous
system, and kidney of adult offspring, probably the
result of DNA damage in fetal rat tissues. Only a few
cases of cancer in pregnancy that used cisplatin in anti-
neoplastic therapy have been reported. Sensorineural
deafness with undetermined cause was reported in one
of the seven cases. Green et al [15] reported that no
congenital malformation was observed in seven liveborn
offsprings treated with cisplatin during childhood or
adolescence.
Fluorouracil is embryotoxic and teratogenic in mice,
rats, and hamsters when given parenteral doses equiv-
alent to the human dose. Multiple fetal defects were
observed during systemic therapy in the first trimester
[16]. Breast cancer during pregnancy using fluorouracil
in antineoplastic therapy have been reported. Giacalone
et al [17] reported the outcomes of pregnancies in 20
women with breast carcinoma who were treated with
antineoplastic agents; the outcomes included two spon-
taneous abortions in the first trimester, one intrauter-
ine fetal death in the second trimester, and 17 live
births, one of whom died after 8 days. The 16 surviv-
ing children developed normally at a mean follow-up
of 42.3 months. We recommend that cisplatin and
fluorouracil use be avoided in the first trimester.
In general, the radiation effects include lethality,
malformations, mental retardation, and cancer induc-
tion [18]. According to the International Commission
on Radiological Protection publication and the Centers
for Disease Control and Prevention [19,20], the dose–
response relationships for mental retardation among
those irradiated at week 8–15 or 16–25 postconcep-
tion were initially reported as linear. A more recent
analysis has evaluated whether the data are supportive
of a threshold using several different models. All the
models that provided a good fit to the data indicated
a threshold for mental retardation for irradiation at
week 8–15 and 16–25 postconception. Besides, the
Taiwan J Obstet Gynecol • December 2007 • Vol 46 • No 4 425
Nasopharyngeal Carcinoma in Pregnancy
results for school performance were similar to those for
IQ. An association between radiation dose and poorer
school performance was seen for those exposed at week
8–15 and 16–25 postconception, with the stronger
trend among those in the week 8–15 group. During the
mid-fetal period, small head size and mental retarda-
tion can often be seen in those with doses exceeding
50 cGy. Small head sizes were seen in two of 30 and two
of 44 children exposed in utero to doses below 10cGy and
between 10 and 50 cGy, respectively. Mental retardation
was observed in 2% for exposures up to 49 cGy.
In conclusion, the possibility of rare NPC should 
be considered in any pregnant woman with the pre-
senting symptoms of persistent headache and nasal
discharge, and a detailed thorough investigation is indi-
cated. Successful pregnancy outcome can be achieved
after tailored use of a combination of chemotherapy
and radiotherapy.
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